Constitutive STAT3 activation in peripheral CD3⁺ cells from patients with primary Sjögren's syndrome

References

• Fox R. I., Tornwall J., Michelson P. Current issues in the diagnosis and treatment of Sjogren's syndrome. Curr Opin Rheumatol 1999; 11: 364–71
   PubMedGoogle Scholar
• Fox R. I., Pearson G., Vaughan J. H. Detection of Epstein–Barr virus‐associated antigens and DNA in salivary gland biopsies from patients with Sjogren's syndrome. J Immunol 1986; 137: 3162–8
   PubMed Web of Science ®Google Scholar
• Skopouli F. N., Fox P. C., Galanopoulou V., Atkinson J. C., Jaffe E. S. Moutsopoulos HM. T cell subpopulations in the labial minor salivary gland histopathologic lesion of Sjogren's syndrome. J Rheumatol 1991; 18: 210–14
   PubMed Web of Science ®Google Scholar
• Moutsopoulos H. M., Zerva L. V. Anti‐Ro (SSA)/La (SSB) antibodies and Sjogren's syndrome. Clin Rheumatol 1990; 9((Suppl 1))123–30
   PubMedGoogle Scholar
• Villarreal G. M., Alcocer‐Varela J., Llorente L. Differential interleukin (IL)‐10 and IL‐13 gene expression in vivo in salivary glands and peripheral blood mononuclear cells from patients with primary Sjogren's syndrome. Immunol Lett 1996; 49: 105–9
   PubMed Web of Science ®Google Scholar
• Garcia‐Carrasco M., Font J., Filella X., Cervera R., Ramos‐Casals M., Siso A., et al. Circulating levels of Th1/Th2 cytokines in patients with primary Sjogren's syndrome: correlation with clinical and immunological features. Clin Exp Rheumatol 2001; 19: 411–15
   PubMedGoogle Scholar
• Llorente L., Richaud‐Patin Y., Fior R., Alcocer‐Varela J., Wijdenes J., Fourrier B. M., et al. In vivo production of interleukin‐10 by non‐T cells in rheumatoid arthritis, Sjogren's syndrome, and systemic lupus erythematosus. A potential mechanism of B lymphocyte hyperactivity and autoimmunity. Arthritis Rheum 1994; 37: 1647–55
   PubMed Web of Science ®Google Scholar
• Moore K. W., de Waal Malefyt R., Coffman R. L., O'Garra A. Interleukin‐10 and the interleukin‐10 receptor. Annu Rev Immunol 2001; 19: 683–765
   PubMed Web of Science ®Google Scholar
• Ohyama Y., Nakamura S., Matsuzaki G., Shinohara M., Hiroki A., Fujimura T., et al. Cytokine messenger RNA expression in the labial salivary glands of patients with Sjogren's syndrome. Arthritis Rheum 1996; 39: 1376–84
   PubMed Web of Science ®Google Scholar
• Jabs D. A., Prendergast R. A., Rorer E. M., Hudson A. P., Whittum‐Hudson J. A. Cytokines in autoimmune lacrimal gland disease in MRL/MpJ mice. Invest Ophthalmol Vis Sci 2001; 42: 2567–71
   PubMed Web of Science ®Google Scholar
• Saito I., Haruta K., Shimuta M., Inoue H., Sakurai H., Yamada K., et al. Fas ligand‐mediated exocrinopathy resembling Sjogren's syndrome in mice transgenic for IL‐10. J Immunol 1999; 162: 2488–94
   PubMed Web of Science ®Google Scholar
• Darnell JE Jr., Kerr I. M., Stark G. R. Jak‐STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994; 264: 1415–21
   PubMed Web of Science ®Google Scholar
• Leonard W. J., O'Shea J. J. Jaks and STATs: biological implications. Annu Rev Immunol 1998; 16: 293–322
   PubMed Web of Science ®Google Scholar
• Levy D. E., Darnell JE Jr. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 2002; 3: 651–62
   PubMed Web of Science ®Google Scholar
• Sengupta T. K., Chen A., Zhong Z., Darnell JE Jr., Ivashkiv L. B. Activation of monocyte effector genes and STAT family transcription factors by inflammatory synovial fluid is independent of interferon gamma. J Exp Med 1995; 181: 1015–25
   PubMedGoogle Scholar
• Krause A., Scaletta N., Ji J. D., Ivashkiv L. B. Rheumatoid arthritis synoviocyte survival is dependent on Stat3. J Immunol 2002; 169: 6610–16
   PubMed Web of Science ®Google Scholar
• Sawa S., Kamimura D., Jin G. H., Morikawa H., Kamon H., Nishihara M., et al. Autoimmune arthritis associated with mutated interleukin (IL)‐6 receptor gp130 is driven by STAT3/IL‐7‐dependent homeostatic proliferation of CD4+ T cells. J Exp Med 2006; 203: 1459–70
   PubMed Web of Science ®Google Scholar
• Lovato P., Brender C., Agnholt J., Kelsen J., Kaltoft K., Svejgaard A., et al. Constitutive STAT3 activation in intestinal T cells from patients with Crohn's disease. J Biol Chem 2003; 278: 16777–81
   PubMed Web of Science ®Google Scholar
• Benkhart E. M., Siedlar M., Wedel A., Werner T., Ziegler‐Heitbrock H. W. Role of Stat3 in lipopolysaccharide‐induced IL‐10 gene expression. J Immunol 2000; 165: 1612–17
   PubMed Web of Science ®Google Scholar
• Vitali C., Bombardieri S., Jonsson R., Moutsopoulos H. M., Alexander E. L., Carsons S. E., et al. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American–European Consensus Group. Ann Rheum Dis 2002; 61: 554–8
   PubMed Web of Science ®Google Scholar
• Hansen A., Lipsky P. E., Dorner T. Immunopathogenesis of primary Sjogren's syndrome: implications for disease management and therapy. Curr Opin Rheumatol 2005; 17: 558–65
   PubMed Web of Science ®Google Scholar
• Perez O. D., Nolan G. P. Simultaneous measurement of multiple active kinase states using polychromatic flow cytometry. Nat Biotechnol 2002; 20: 155–62
   PubMed Web of Science ®Google Scholar
• Anaya J. M., Mantilla R. D., Correa P. A. Immunogenetics of primary Sjogren's syndrome in Colombians. Semin Arthritis Rheum 2005; 34: 735–43
   PubMedGoogle Scholar
• Font J., Garcia‐Carrasco M., Ramos‐Casals M., Aldea A. I., Cervera R., Ingelmo M., et al. The role of interleukin‐10 promoter polymorphisms in the clinical expression of primary Sjogren's syndrome. Rheumatology (Oxford) 2002; 41: 1025–30
   PubMed Web of Science ®Google Scholar
• Marka M., Bessenyei B., Zeher M., Semsei I. IL‐10 promoter –1082 polymorphism is associated with elevated IL‐10 levels in control subjects but does not explain elevated plasma IL‐10 observed in Sjogren's syndrome in a Hungarian cohort. Scand J Immunol 2005; 62: 474–80
   PubMed Web of Science ®Google Scholar
• Akira S., Nishio Y., Inoue M., Wang X. J., Wei S., Matsusaka T., et al. Molecular cloning of APRF, a novel IFN‐stimulated gene factor 3 p91‐related transcription factor involved in the gp130‐mediated signaling pathway. Cell 1994; 77: 63–71
   PubMed Web of Science ®Google Scholar
• Zhong Z., Wen Z., Darnell JE Jr. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin‐6. Science 1994; 264: 95–8
   PubMed Web of Science ®Google Scholar
• Hirano T., Ishihara K., Hibi M. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL‐6 family of cytokine receptors. Oncogene 2000; 19: 2548–56
   PubMed Web of Science ®Google Scholar
• Heinrich P. C., Behrmann I., Muller‐Newen G., Schaper F., Graeve L. Interleukin‐6‐type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J 1998; 334: 297–314
   PubMed Web of Science ®Google Scholar
• Levy D. E., Lee C. K. What does Stat3 do?. J Clin Invest 2002; 109: 1143–8
   PubMed Web of Science ®Google Scholar
• Alexander W. S., Hilton D. J. The role of suppressors of cytokine signaling (SOCS) proteins in regulation of the immune response. Annu Rev Immunol 2004; 22: 503–29
   PubMed Web of Science ®Google Scholar